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ABSTRACT 
 
 
Lysophosphatidic acid (LPA), a naturally-occurring, simple phospholipid, is present at 
elevated levels in the blood and ascites of ovarian cancer patients. LPA is a ligand of seven 
cell surface G protein-coupled receptors. It has been known as an oncogenic growth factor in 
ovarian cancer and other types of human malignancies. However, the precise biological 
functions of LPA in ovarian oncogenesis remain to be fully elucidated. Our laboratory is 
interested in studying the potential role of LPA, as a tumor microenvironment factor, in 
regulation of cancer cell metabolism. A fundamental change associated with most cancer is 
the switch of glucose metabolism from mitochondrial oxidative phosphorylation to aerobic 
glycolysis, a phenomenon described by Otto Warburg nearly a century ago. This seems to be 
necessary to meet bioenergetic and biosynthetic demands of rapidly dividing tumor cells. 
However, the mechanism underlying the switch from aerobic respiration to aerobic glycolysis 
in cancer cells remains poorly understood. 
In this thesis project, my goal was to explore the effect of LPA on glycolysis and to 
compare LPA with other important growth factors in their capability to promote the glycolytic 
pathway in ovarian cancer cells. We demonstrated that LPA stimulated aerobic glycolysis as 
xviii 
 
well as cell proliferation in ovarian cancer cell lines. The two parallel responses were LPA 
dose dependent. To determine whether LPA is unique in driving glycolysis, we compared the 
effect of LPA with other growth factors, including EGF, insulin and IGF-1 which are all 
involved in pathogenesis of ovarian cancer. While doses of these growth factors could be 
adjusted to achieve similar levels of cell proliferation, LPA and EGF were much more potent 
than insulin and IGF-1 in stimulation of glycolytic flux and lactate production. Therefore, we 
identified LPA and EGF as highly glycolytic factors relevant to the development and 
maintenance of the glycolytic phenotype of ovarian cancer cells.  
The next part of my study was focused on the molecular mechanism for the differential 
effects of LPA, EGF, insulin and IGF-1 on glycolytic metabolism. We used the glucose 
metabolism RT-PCR array to profile expression of glycolytic genes. The most remarkable 
change induced by LPA and EGF was the robust induction of hexokinase 2 (HK2) that 
stimulates irreversible entry of glucose to the glycolytic pathway. However, insulin and IGF-1 
only weakly induced HK2 expression. Further experimental evidence using HK2 inhibitors 
indicated that HK2 up-regulation was the critical mediator of LPA-induced glycolysis. 
Further, the cells grown in LPA and EGF-stimulated conditions appear to show larger volume 
compared to insulin and IGF-1-treated cells, consistent with the hypothesis that active 
glycolysis contributes to biosynthetic processes to maintain cell sizes.  
Taken together, these findings of the current study revealed high glycolytic effects of 
LPA and EGF in ovarian cancer and the underlying HK2-mediated mechanism that 
distinguishes LPA and EGF from other growth factors such as insulin and IGF-1. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
1.0 Overview 
 
Ovarian cancer begins in the ovary and the most common type of ovarian cancer is 
ovarian epithelial carcinoma (PubMed Health 2012). The American Cancer Society estimates 
that about 21,990 new cases of ovarian cancer are diagnosed in the United States in 2012. It 
is the 8
th
 most common cancer in women but is the most lethal gynecological malignancy 
(American Cancer Society Ovarian Cancer Overview 2012).  
Ovarian cancer is classified into four stages (Stages I-IV). At stage I, the tumor is 
limited to one or both ovaries. The tumor has pelvic extension or implants at stage II. At the 
advanced stages III and IV, ovarian cancer often spreads beyond pelvis, to the peritoneal 
cavity， and becomes distant metastases in the liver and other parts of the body. When the 
tumor is still restricted to the primary site, the 5-year survival rate is more than 90% 
(American Cancer Society Ovarian Cancer Overview 2012). However, the American cancer 
survival rate survey showed that ovarian cancer is the 5
th
 cause of cancer death among 
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women and the overall 5-year survival rate is only 28% largely due to the inability to detect 
the ovarian cancer at early curable stages and the lack of effective therapies for advanced 
disease (American Cancer Society Ovarian Cancer Overview 2012). The standard 
management of ovarian cancer remains surgical debulking of tumor mass followed by 
chemotherapeutic treatment. Relapse with drug-resistant phenotype usually occurs, leading to 
eventual deaths of ovarian cancer patients (Armstrong D. 2002). For these reasons, it is 
critical to identify ovarian cancer at early stages or to develop effective therapies against 
late-stage ovarian cancer. These missions, however, rely on better understanding of 
pathogenic processes underlying the initiation and progression of ovarian cancer.  
Genetic and epigenetic alterations in tumor suppressors and oncogenes play pivotal 
roles in malignant transformation of ovarian epithelial cells (Herceg Z., Hainaut P. 2007). 
However, accumulating evidence supports the involvement of tumor micro-environmental 
factors including interacting stromal cells, immune cells and diffusible molecules act in 
concert with intracellular genetic mutation and activation to mediate oncogenic processes 
(Zhang X., Nie D., Chakrabarty S. 2010). Our lab has a long-standing interest in the 
biological contributions of lysophosphatidic acid (LPA) to the development of human ovarian 
cancer. LPA is present at high levels in the ascites of ovarian cancer patients and other 
malignant effusions (Mills G. B. et al. 1988 & 1990; Xu Y. et al. 1995; Westermann A. M. et 
al. 1998). Previous studies from others as well as our laboratory have demonstrated that LPA 
promotes proliferation, survival, drug resistance, migration and invasion of ovarian and other 
cancer cells. Specific LPA receptors, such as LPA2, are overexpressed in ovarian cancer cells 
and ovarian cancer cell lines (Kitayama J, et al. 2004). However, the exact mechanism by 
which LPA drives tumor cell growth remains poorly understood. Recently we have evaluated 
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the role of LPA in regulation of tumor cell metabolism to ask whether LPA drives cell growth 
via up-regulating energy and biomass production. This is a new concept that has not been 
studied in the field of LPA biology. In this thesis, I focused on the effect of LPA on glycolytic 
metabolism and compared the effect with those of other prominent growth factors relevant to 
ovarian cancer.  
 
 
1.1 LPA 
 
1.1.1 Metabolism of LPA 
 
LPA (1-acyl-2-hydroxy-sn-glycero-3-phosphate) is a naturally-occurring simple 
phospholipid. It contains a single fatty acyl chain, a glycerol backbone and a phosphate group. 
LPA could be produced by many different types of cells, for example, activated platelets, 
endothelial cells, fibroblasts, adipocytes, prostate and ovarian cancer cells. LPA is present in 
various body fluids. For instance, the concentrations of LPA in serum are about 1-5μM. LPA 
is present in high levels in ascites of ovarian cancer ascites and other malignant effusions. In 
human blood, most LPA forms are 16:0, 18:2, and 18:1-LPA (Sano T, et al. 2002) and the last 
form is the most commonly used laboratory reagent for LPA signaling studies. LPA is an 
extracellular mediator that evokes growth-factor-like responses in many cell types, both 
normal and transformed cells. The major biological actions of LPA include promotion of cell 
proliferation, survival, migration, and invasion (Moolenaar W. H. 1989). 
Two major synthetic pathways are involved in the production of LPA (Mills GB, 
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Moolenaar WH, 2003). The first route is mediated by the action of phospholipases, secretory 
phospholipase A2 (sPLA2) and phospholipase A1 (PLA1). These phospholipases cleave the 
fatty acyl chain of phospholipids at the sn-2 or sn-1 position. The resulting lysophospholipids, 
such as lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE) and 
lysophosphatidylserine (LPS), can be converted to LPA by lysophospholipase D 
(lysoPLD/ATX), which has the ability to hydrolyze LPC, LPE and LPS. This route has been 
identified to be the primary synthetic pathway of LPA in the blood involving activated 
platelets. The other route of LPA production involves the action of monoacylglycerol kinase 
that phosphorylates monoacylglycerol (MAG) to form LPA. 
On the other hand, extracellular LPA levels are controlled by lipid phosphate 
phosphatases (LPPs), a family of enzymes located on cell membranes with the catalytic sites 
facing extracellular space (Mills GB, Moolenaar WH, 2003). LPPs dephosphorylate LPA to 
form MAG which loses the biological activity of LPA. Thus overexpression of LPPs in 
ovarian cancer cells is associated with inhibition of LPA signaling, leading to increased 
cellular apoptosis and inhibition of tumor cell growth both in vitro and in vivo (Tanyi, J. L. et 
al. 2003). Besides, LPA could be also catabolized via acylation to phosphatidic acid (PA) by 
the action of LPA acyl transferases (LPAAT) (Mills GB, Moolenaar WH, 2003). 
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1.1.2 LPA receptors 
 
In addition to cell proliferation, survival, migration, and tumor cell invasion, LPA had 
been also shown to regulate wound healing, cell contraction, neurogenesis, angiogenesis and 
immunity (Moolenaar WH, 1995; Mills GB, Moolenaar WH, 2003). These biological 
functions of LPA are mediated by a number of G-protein coupled LPA receptors (GPCRs). So 
far, seven GPCRs have been identified to be receptors for LPA (Noguchi K, et al. 2009; 
Yanagida K, et al. 2009). The best-characterized are LPA1/Edg2, LPA2/Edg4 and LPA3/Edg7. 
They are members of the endothelial differentiation gene (Edg) super-family, where receptors 
for another related lysophospholipids, sphingosine-1-phosphate (S1P), are found (Noguchi K, 
et al. 2009). The three Edg LPA receptors share about 50-60% amino acid identity. In addition, 
newly identified LPA receptors, LPA4/GPR23/P2Y9, LPA5/GPR92/GPR93, LPA6/P2Y5 and 
LPA7/GPR87 belong to the purinergic receptor family, sharing little sequence homology with 
the Edg LPA receptors (Noguchi K, et al. 2009).  
LPA1 is the first identified high-affinity GPCR for LPA (Fukushima N, et al. 2001; Ishii 
I, et al. 2004). It is widely expressed in the embryonic cells, colon, small intestine, placenta, 
brain, uterus, testis, lung, stomach, kidney, spleen, thymus, skeletal muscle and heart tissues 
(Hecht, J.H. et al. 1996). LPA1 couples with three types of G proteins, Gαq, Gαi and 
Gα12/13. These G proteins can activate further downstream signaling pathways, leading to 
activation of Ras-MAPK, PI3K-AKT, PLC and Rho to regulate cell proliferation, survival, 
migration, and invasion (Ishii et al., 2000; An et al., 1998b; Erickson et al., 1998). However, 
there is no consensus evidence that this LPA receptor is overexpressed in ovarian cancer or 
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other malignancies (Fang X. 2002).  
LPA2 was originally identified from GenBank searches of orphan GPCRs. It shares 
about 60% amino acid similarity to LPA1 (Contos J., et al. 2000). The expression of LPA2 is 
relatively restricted compared to LPA1. In mouse, LPA2 is highly expressed in kidney, uterus 
and testis and lung; but lower levels of expressions are discovered in stomach, spleen, thymus, 
brain and heart (Contos JJ, et al. 2000). Over-expression of LPA2 has been reported in many 
types of cancer including ovarian, breast, colon, gastric, and thyroid cancer, suggesting a 
tumor-promoting role for LPA2 (Choi J, et al. 2010). Indeed, transgenic expression of LPA2 
leads to mammary tumorigenesis when the LPA2 gene is driven by the MMTV (mouse 
mammary tumor virus) promoter (Liu S, et al. 2009). Ovarian specific transgenic expression 
of LPA2 is linked to enhanced expression of oncogenic VEGF (vascular endothelial growth 
factor) and uPA but is insufficient for ovarian oncogenesis (Huang MC, et al. 2004). The most 
direct evidence to implicate LPA2 in cancer is derived from the recent studies by Yun’s group 
using the LPA2 null mice (Yun CC et al. 2005). Mice lacking LPA2 do not show any 
significant abnormalities in physiology. However, compared to wild type mice, the 
LPA2-deficient mice were more resistant to intestinal tumor formation induced by colitis or 
by ApcMin mutation.  
LPA3 was originally identified as an orphan GPCR gene using degenerate PCR-based 
cloning and homology searches. (Bandoh et al. 1999; Im et al. 2000) It has about 50% amino 
acid similarities with the first two LPA receptors. It is expressed in many tissues, such as 
heart, lung, kidney and exclusively in the luminal endometrial epithelium (Ye X, et al. 2005). 
Like LPA1 and LPA2, LPA3 activates Gαq and Gαi to mediate LPA induced activation of 
phospholipase C and calcium mobilization, and inhibition of adenylyl cyclase (AC) (Ishii et 
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al., 2000). However, LPA3 does not couple with Gα12/13, and therefore does not activate 
Rho GTPase.   
LPA4 is closely related to the purinergic (P2Y) GPCR family (Choi J, et al. 2010). It 
was first identified through the analysis of the expressed sequence tag database. LPA4 gene is 
located on chromosome X and has a specific binding affinity to LPA ligand, but not to other 
lysophospholipids (Noguchi et al. 2003). Overexpression of LPA4 induces changes in cell 
morphology, such as stress fiber formation and neurite retraction through the activation of 
Gα12/13 and the Rho/Rho kinase pathway (Lee et al. 2007; Yanagida et al. 2007).  
LPA5 was identified as an orphan GPCR which belongs to the rhodopsin GPCR family 
and structurally different from other LPA receptors (Lee C, et al. 2007). Functional studies 
showed LPA5 induces neurite retraction and stress fiber formation by activating Gα12/13, 
and triggered calcium signaling by coupling to Gαq (Lee et al. 2006). Furthermore, it 
increases cAMP levels and PKA activation in LPA5-expressed cells (Kotarsky et al. 2006).  
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1.1.3 LPA and Cell Proliferation 
 
LPA as a growth factor was first reported in fibroblasts (Van der Bend et al., 1992). 
Subsequently, the mitogenic activity of LPA was found in many other cell types, including 
normal and transformed cells (Huang et al. 2004). LPA drives cell proliferation through the 
pertussis toxin (PTX) sensitive Gαi pathway (Fang et al. 2000; Van Corven et al. 1992). Gαi 
induces the inhibition of intracellular adenylyl cyclase, activating the downstream Ras-Erk 
and PI3K-AKT pathways which are essential for cell proliferation (Fang et al. 2000; 
Kingsbury et al. 2003). The active Erk translocates to the nucleus where it activates the 
expression of proliferation-associated genes. In addition, both Erk and PI3K promote cell 
survival and inhibit apoptosis (Hafner A. et al. 2012; Ostrakhovitch EA, Cherian MG. 2005; 
Bondar V. et al. 2002). 
 
 
 
 
1.2 Receptor Tyrosine Kinases 
 
    In addition to the GPCR family, the largest group of cell surface receptors (Fredriksson 
R. et al. 2003), receptor tyrosine kinases constitutes another receptor family important in the 
regulation of cell proliferation and cancer development (Schlessinger J and Ullrich A. 1992). 
The prototype example is the receptor for epidermal growth factor (EGF). The ligands for 
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EGFR include EGF, transforming growth factor (TGF) and heparin-binding EGF (HB-EGF) 
(Hubbard SR and Till JH. 2000). Upon activation by its ligands, EGFR undergoes a transition 
from an inactive monomeric form to an active homodimer. EGFR dimerization stimulates its 
intrinsic intracellular tyrosine kinase activity, causing auto-phosphorylation of several 
tyrosine (Y) residues in the C-terminal domain of EGFR (Lemmon MA and Schlessinger J. 
2010). These phosphorylated tyrosine resides will serve as sites for interacting with 
downstream signaling molecules to initiate several signal transduction cascades, leading to 
cell proliferation and migration (Schlessinger J and Ullrich A. 1992). 
It has become clear that EGFR and other members of EGFR family such as ErbB2 are 
overexpressed in many types of malignancies including ovarian and breast cancer (Walker F. 
et al. 2009). Moreover, activating mutations in the C-terminal kinase of EGFR are common in 
colon, lung and other major types of cancer, affecting tumor progression and drug resistance 
to chemotherapies (Lynch TJ, et al. 2004). Therefore EGFR-targeted therapies using 
anti-EGFR antibodies or small molecule inhibitors have been in clinical applications for 
cancer treatment (Jackman DM. et al. 2009; El-Sayed IH. Et al. 2006). 
Insulin-like growth factor (IGF) is a potent growth factor present in the blood to 
stimulate growth of multiple cell types (Laron Z. 2001). Insulin, in addition to its metabolic 
role, also possesses mitogenic activity (Ish-Shalom D. et al. 1997). Insulin and IGF have been 
implicated in ovarian oncogenesis (Beauchamp MC. 2009). Ample evidence supports a role 
for IGF-1 in ovarian cancer through increased cell growth (Laron Z. 2001). The signal 
transduction of insulin and IGF-1 receptor tyrosine kinases is similar to that of EGFR. But, 
they are stronger activators of PI3K/AKT pathway than EGFR (Duncan MD. et al. 1994; 
Harrington LS. Et al. 2004). In addition, the activities of IGF-1/receptor systems are 
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regulated both positively and negatively by a series of IGF-binding proteins (IGFBPs) present 
in the blood (Hwa V, Oh Y, Rosenfeld RG. 1999). Intracellularly, insulin receptor (IR) and 
IGFR differ from EGFR in the presence of IR substrate 1 that transmits signals from 
activated IR or IGFR to downstream signaling cascades. 
 
 
 
 
1.3 Cancer Cell Metabolism 
 
Cancer cells are characterized by lipogenic and glycolytic phenotypes. Different from 
non-transformed cells, malignant cells display heightened de novo lipid synthesis, as well as, 
hyperactive aerobic glycolysis. Our lab has recently reported a role of LPA in activation and 
maintenance of lipogenic activity in ovarian cancer cells (Mukherjee A. et al. 2012). However, 
it is unknown whether LPA has a more profound effect on glucose utilization.  
The glycolysis pathway converts one molecule of glucose into two molecules of 
pyruvate in association with formation of two ATPs (Figure 1.2). Under normoxia, most 
normal cells produce energy by glycolysis followed by oxidation of pyruvate in mitochondria 
(TCA cycle). The TCA cycle coupled to the respiration chain eventually generates a total of 
36 ATPs from 1 molecule of glucose. Alternatively, pyruvate can be converted to in the 
absence of oxygen. Cancer cells prefer glycolysis even in the presence of oxygen, a 
phenomenon first observed by Dr. Otto Warburg nearly a century ago (Warburg, O. 1956). 
Most cancer cells produce energy by a high rate of glycolysis followed by lactic acid 
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formation in the cytosol, rather than by a comparatively low rate of glycolysis followed by 
complete oxidation of pyruvate in mitochondria as in most normal cells (Figure 1.1).  
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Figure 1.1 Aerobic glycolysis (Warburg Effect). Redraw figure and include in legend 
“adapted from Vander Heiden, et al. 2009”  
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A high rate of glycolysis seems to be advantageous to meet bioenergetic and biosynthetic 
demands of rapidly dividing tumor cells (Lnt, S. et al. 2011). Cancer cells rely on the 
glycolytic metabolism for growth, survival and chemo-resistance. The mechanism underlying 
the switch from aerobic respiration to aerobic glycolysis in cancer cells remains poorly 
understood. Hypoxia and acidic pH stimulate glycolysis through stabilization of the 
hypoxia-inducible transcription factor (HIF) to activate transcription of a number of 
glycolytic genes (Kim JW. et al. 2006). However, hypoxia and acidic microenvironment are 
not causal factors of the glycolytic phenotype that occurs in both hypoxic and oxygenated 
regions of a tumor (Onnis B. et al. 2009; Wang GL. et al. 1995). Tumor cells in vitro also 
utilize glycolysis when cultured in normoxic and neutral conditions. Ras, AKT, and c-Myc 
have been reported to up-regulate expression of various glycolytic enzymes (Riddle SR. et al. 
2000; Allen CB. et al. 1998). Loss of the tumor suppressor p53 inhibits the mitochondrial 
respiratory chain via suppression of SCO2 (the synthesis of cytochrome c oxidase protein) 
and promotes glycolysis via TIGAR, a TP53-induced glycolysis and apoptosis regulator (Kim 
JW. et al. 2006). In addition, the mitochondrial respiratory function can be impaired by 
mutations in mitochondrial DNA. However, it is not clear whether these genetic defects are 
sufficient for the development and maintenance of the glycolytic phenotype seen in a wide 
spectrum of cancers. 
Previous studies of cancer-associated glycolysis have overlooked potential inputs from 
abnormal growth-promoting signals present in the tumor microenvironment that could trigger 
a glycolytic response in cooperation with the above-mentioned genetic aberrations in tumor 
cells. This differs from self-controlled glycolysis associated with proliferation of normal cells 
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where the growth activities are transient and restrained by the normal regulatory machinery.  
In this thesis work, we hypothesize that LPA, a lysophospholipid mediator present at 
high levels in ascitic fluids of ovarian cancer patients, is a pathophysiological factor to drive 
glycolysis in ovarian cancer. I tested the hypothesis by comparing the effect of LPA on 
glycolysis with those of other peptide growth factors implicated in ovarian cancer 
pathogenesis, namely EGF, IGF-1 and insulin. Our results indicate that LPA and EGF are 
potent stimuli of glycolysis in ovarian cancer lines, while insulin and IGF-1 only modestly 
increased the cellular glycolytic activity although they showed similar mitogenic activities. I 
performed the glucose metabolic arrays covering all glycolytic enzymes in order to 
understand the molecular mechanism underlying the differential effects of LPA, EGF, insulin 
and IGF-1 on glycolysis. The array results indicate that LPA and EGF strongly induce 
expression of hexokinase 2 (HK2) that catalyzes the first rate-limiting step of glycolytic 
reactions. In contrast, insulin only slightly activated expression of HK2 compared to LPA and 
EGF. The data highlights the importance of HK2 as a major mediator of hyperactive 
glycolysis in ovarian cancer cells. Thus, targeting LPA-HK2 or EGF-HK2 could offer 
therapeutic opportunities to disrupt glycolysis in a cancer cell-specific manner. The 
differential effects of LPA, EGF, insulin and IGF-1 also open a new research avenue to 
explore the relationship of glycolysis and cell growth.  
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(Reproduced from Biology MOOC Newsletter Archive, Daily Newsletter: Oct. 2, 2012- 
Glycolysis Part 2) 
Figure 1.2 The glycolytic pathway 
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CHAPTER 2 
 
 
MATERIALS AND METHODS 
 
Reagents  
LPA (1-oleoly, 18:1) was obtained from Avanti Polar Lipids, Inc. (Alabaster, AL). Prior 
to use, LPA was dissolved in PBS containing 0.5% fatty acid-free bovine serum albumin 
(BSA) purchased from Roche Applied Science (Indianapolis, IN). Glucose (D-[5-
3
H(N)]-) 
was obtained from Perkin Elmer (Boston, MA). Fetal bovine serum (FBS) was obtained from 
Atlanta Biologicals (Atlanta, GA). All other cell culture reagents were obtained from 
Invitrogen Inc. (Carlsbad, CA). Scintillation solution, Complete Counting Cocktail 
Budget-Solve was purchased from Research Products International Corp. (Mount Prospect, 
IL). Reverse transcription kit, TaqMan gene expression assays, Universal PCR Master Mix 
and qPCR probes were obtained from Applied Biosystems (Carlsbad, CA).  
 
Cell Culture 
    The sources of Caov3, OVCA432 and other ovarian cancer cell lines were described 
previously (Fang et al. 1998). These cells were cultured in RPMI 1640 supplemented with 10% 
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FBS, L-Glutamine (1 mM) and antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin). 
All cell lines were frozen at early passages and used for <10 weeks in continuous culture. 
 
Analysis of Cell Proliferation  
Caov3 and OVCA432 cells were cultured in 6-well plates, starved for 24 hours and 
treated with LPA, EGF, insulin or IGF-1 at concentrations indicated. Approximately 36-40 
hours later, the cells were trypsinized with 0.25% Trypsin-EDTA and neutralized with 
complete culture medium. The cell viabilities were determined by trypan blue exclusion 
assessed with the Bio-Rad TC
10
 automatic cell counter, which was usually more than 95%. 
The cell numbers were quantified with the Z1 Coulter counter (Beckman Coulter, FA). The 
results were presented as net increases induced by indicated growth factors (the numbers of 
cells prior to treatment were subtracted). All results were mean ± S.D. of replicates. 
 
Analysis of Glycolytic Rate 
The glycolytic rates were determined using a modified version of the Elstrom et al. 
(2004) method, measuring conversion of 5-
3
H-glucose to 
3
H-H2O, presented as percentage 
(%) conversion of glucose. The details of the method are summarized in Figure 2.1. Caov3, 
OVCA432 and other ovarian cancer cell lines were plated in 6-well plates, starved in 
serum-free medium for 24 hours and then stimulated with LPA, EGF, insulin, or IGF-1 at 
indicated concentrations. After 12 hours, D-[5-
3
H(N)]-glucose was added to the medium at a 
concentration of 2 μCi/well and incubated for another 24 hours before collection of 0.5 ml 
culture medium into a 15 ml tube. Hydrochloric acid (1.2 M) was added to a final 
concentration of 0.2 M to terminate any further biological reactions. A 0.5 ml micro 
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centrifuge tube without cap containing 0.25 ml distilled water was inserted into the 15 ml 
tube. Precautions were taken to ensure that the two liquid phases remained separate during 
incubation. The 15 ml tube was capped tightly to allow vapor diffusion of the water 
component between the two liquid phases for more than 36 hours. At the end of incubation, 
the radioactivity present in 0.25 ml water in the 0.5 ml tube (reflecting 
3
H-H2O) and 
radioactivity present in 0.25 ml solution taken from the 15 ml tube (representing both 
3
H-H2O 
and 
3
H-glucose) were quantified by Scintillation counting using complete Counting Cocktail 
Budget-Solve from Research Products International Corp. (Mount Prospect, IL) and the LS 
6500 Multi-Purpose Scintillation Counter. The ratios of the radioactivities present in water 
and in medium were presented as glycolytic rates. All results were mean ± S.D. of replicates 
During the glycolysis, one molecule of water is released from one molecule of 
2-phosphoglycerate, so that 2-phosphoglycerate could convert to phosphoenolpyruvate which 
then produces pyruvate (see Figure 1.2). In our study, we utilized glucose at a tritium on C
5
. 
In the glycolysis pathway, this labeled glucose would release one molecule of tritium labeled 
water to the media. By measuring the ratio of radioactive 
3
H-H2O versus total radioactivity 
(
3
H-glucose+
3
H-H2O), we are able to quantitate the glycolytic rate in the cells. 
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Figure 2.1 Experimental protocol for measurement of glycolysis rate 
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Lactate Measurement 
    Cells were plated in 6-well plates, starved in serum-free medium for 24 hours and then 
treated with BSA, LPA, EGF, insulin, or IGF-1 for 36-40 hours before the culture 
supernatants were collected. The culture medium was centrifuged at 1500g to remove any 
floating cells. The lactate concentrations in the medium were determined using the L-Lactate 
Assay Kit I purchased from Eton Bioscience (San Diego, CA) following the manufacturer’s 
protocol. 
 
PCR array 
    The Human glucose metabolism, RT
2
 profiler PCR Arrays (PAHS-006Z) were obtained 
from SABiosciences. Caov3 cells in 60 mm dishes were starved for 24 hours in serum-free 
medium and treated with LPA, EGF, insulin or BSA (vehicle) for 12 hours before RNA 
isolation using RNeasy Mini Kit (Qiagen). Complementary DNA (cDNA) was synthesized 
using RT
2
 First Strand Kit (Qiagen) and qPCR was carried out using RT
2
 SYBR® Green 
qPCR Master Mix (Qiagen) according to the manufacturer’s protocol. 
 
Analysis of cell morphology and cell size  
    After treatment for 36 hours with LPA, EGF, insulin or IGF-1, the morphology of Caov3 
and OVCA432 cells in 6-well plates was examined with phase-contrast microscope. The 
microscopic photographs were taken at varying magnifications. After trypsinization, the size 
ranges of cells in suspension were analyzed with the Bio-RAD TC
10
 Automated Cell Counter. 
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Statistics  
    All numerical data were presented as mean ± SD of triplicates. The results were 
confirmed by three independent experiments. The statistical significance of differences was 
analyzed using Student’s t test where p＜0.05 was considered statistically significant. In all 
figures, the statistical significances were indicated with * if p＜0.05 or ** if p＜0.01. 
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CHAPTER 3 
 
 
RESULTS 
 
3.1 LPA promotion of glycolysis and cell proliferation in ovarian cancer cells 
 
LPA has been long been known as a mediator of ovarian cancer and other types of 
cancers (Mills G. B. et al. 1988). It is present in the blood and ascitic fluids of ovarian cancer 
patients (Mills G. B. et al. 1990). LPA stimulates proliferation, survival, migration and 
invasion of ovarian cancer cells. These effects are mediated by several GPCR receptors of 
LPA and specific downstream signaling cascades such as Gi-linked Erk and PI3K signaling 
cascades (Moolenaar W. H. et al. 1995). However, mechanistic studies to elucidate further 
molecular programs leading to these events such as cell proliferation are lacking. Recent 
studies suggest that metabolic reprogramming is implicated in driving cell proliferation (Fang 
X. et al. 2002). For example, dividing cells need to gain sufficient precursors to synthesize 
DNA, proteins and phospholipids in completion of mitosis. A few studies have shown that 
LPA signaling modifies metabolic features of cancer cells (Fang X. et al. 2002). The only 
clue in the literature that LPA may be capable of activating glycolysis is derived from 
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Bernhart et al. (2010). This study reported that LPA increased expression of glycolytic 
enzymes in the C13NJ microglia cell line. We and others have previously demonstrated that 
LPA treatment of ovarian cancer cells leads to stabilization of hypoxia-inducible factor (HIF), 
a transcription factor potentially involved in activation of glycolytic genes (Allen CB. et al. 
1998; Kim JW. et al. 2006).  
Therefore, we have examined whether LPA can promote glycolysis in ovarian cancer 
cell lines. As shown in Figure 3.1, LPA stimulated multi-fold increases in glycolytic flux in 
both Caov3 and OVCA432 cells. This effect was also seen in other cell ovarian cancer cell 
lines (data not shown). We compared the effects of LPA on glycolysis as well as cell 
proliferation and found that the two responses occur in parallel, both in a LPA-dose 
dependent manner. These effects reached a plateau at 10 μM LPA. In addition to the 
dose-dependent effects of LPA, the detected glycolytic flux increased with the incubation 
time of 
3
H-glucose. When incubated for only 6 hours, we observed a less than 2.5 fold 
increased in glycolysis. However, when this was extended to 24 hours of incubation, the 
reading increased to 3 fold (Figure 3.2), indicating that the effect of LPA on glycolysis was 
sustained.     
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Figure 3.1 LPA stimulated multi-fold increases in glycolytic rate and cell numbers in both 
Caov3 and OVCA432 cells. 
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Figure 3.2 Time dependence of LPA-stimulated glycolysis. 
3
H-glucose was incubated with 
Caov3 cells for the last 6 hours or last 24 hours before analysis of glycolysis.  
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3.2. Differential effects of LPA and other growth factors on glycolysis 
 
To determine whether LPA is unique in driving glycolysis, we compared the effect of 
LPA with other growth factors involved in pathogenesis of ovarian cancer. These include EGF, 
insulin and IGF-1. We first tested different concentrations of EGF, insulin and IGF-1 in order 
to identify the doses that elicited mitogenic responses at levels similar to 10 μm LPA. As 
shown in Figure 3.3, in Caov3 cells, EGF (40 ng/ml), insulin (10 μg/ml), IGF-1 (20 ng/ml) 
and LPA (10 μM) triggered comparable levels of proliferation. In OVCA432 cells, similar 
cell proliferation was achieved at 2 ng/ml EGF, 0.125 μg/ml insulin, 25 ng/ml IGF-1 and 10 
μM LPA. These results suggest that these growth factors are all potent mitogenic factors in 
ovarian cancer cells. 
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Figure 3.3 Caov3 and OVCA432 cells were stimulated with LPA, EGF, insulin or IGF-1 at 
the indicated concentrations for 36-40 hours. The cell numbers were determined with Coulter 
counter and presented as net increases induced by the growth factors (the numbers of cells 
prior to treatment were subtracted). 
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We next examined whether these other growth factors also stimulated glycolytic 
metabolism while promoting similar levels of cell proliferation. The glycolytic flux was 
measured as in Fig. 2.1 (Chapter 2) and concentrations of lactate present in culture 
supernatants were quantified using the Lactate Assay Kit I.  These results in Caov3 and 
OVCA432 are presented in Fig. 3.4, and Fig. 3.5, respectively.  
LPA and EGF stimulated more glycolysis than insulin and IGF-1. In Caov3 cells, 
glycolytic conversion of glucose was increased from 4.6% in the unstimulated control cells to 
12.5% by LPA, 15.3% by EGF. In contrast, insulin and IGF-1 stimulated statistically 
significant but much weaker increases (from 4.6% basal control to 6.8 % by insulin, and to 
7.1% by IGF-1) (Figure 3.4, left panel). Similarly, LPA and EGF stimulated more lactate 
production as reflected by much higher lactate concentrations in the culture medium than in 
insulin or IGF-1 conditioned medium (Figure 3.4, right panel).  
We observed similar effects of LPA, EGF, insulin and IGF-1 on glycolysis and lactate 
production in OVCA432 cells (Figure 3.5). The comparisons suggest that the growth factors 
are not equivalently glycolytic in spite of showing similar mitogenic activities. In other words, 
there exist two types of growth factors: highly glycolytic, such as LPA and EGF, or weakly 
glycolytic, represented by insulin and IGF-1.  
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Figure 3.4 Differential effects of LPA, EGF, insulin and IGF-1 on glycolysis and lactate 
production in Caov3 cells. Values for LPA, EGF, IGF and insulin are significantly higher than 
BSA (p<0.1). 
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Figure 3.5 Differential effects of LPA, EGF, insulin and IGF-1 on glycolysis and lactate 
production in OVCA432 cells. Values for LPA, EGF, IGF and insulin are significantly higher 
than BSA (p<0.1). 
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3.3. Differential effects of LPA and other growth factors on expression of glycolytic 
genes 
 
To determine the molecular mechanism for the differential effects of growth factors on 
glycolytic metabolism, we performed glucose metabolism arrays. We treated Caov3 cells 
with LPA (10 μM), EGF (40 ng/ml), or insulin (10 μg/ml) for 12 hours, isolated the RNA for 
micro RT-qPCR array to determine mRNA expression changes of genes involved in glucose 
metabolism (SABioscience). As shown in Figure 3.6, the array covers 84 key genes involved 
in glucose metabolism including all glycolytic enzymes. As shown in Figure 3.7, there was 
significant overlap of up and down-regulated genes responsive to LPA and EGF. HK2, the 
enzyme catalyzing the irreversible first rate-limiting step of glucose metabolism was found to 
be most markedly up-regulated by LPA (39 fold) and by EGF (22 fold) (see Figure 3.8).  
HK2 overexpression or hyperactivity is common in malignant cells, which constitutes 
the physiological basis for cancer detection by 2’-fluoro-2’deoxy-D-glucose positron 
emission tomography (FDG-PET) scans. A number of glucose metabolic enzymes were 
repressed by LPA and EGF. Among them, PDK4 was inhibited by 20 and 10 fold in LPA- and 
EGF-treated cells, respectively. PDK4 and its isozyme PDK2 (also significantly 
down-regulated by LPA and EGF) are key regulatory kinases that phosphorylate and 
inactivate PDH complex and thus control the metabolic fate of pyruvate (Grassian AR, et al. 
2011; Jeong JY, et al. 2012). HK2 was also the most up-regulated gene in response to insulin. 
However, the magnitude of induction (4.2 fold up) was much weaker than those of LPA and 
EGF, consistent with the less active glycolysis in insulin-treated cells. In addition, the effects 
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of insulin on PDK4 (2.2 fold down) and PDK2 (1.4 fold down) were marginal. Instead, the 
most down-regulated glycolytic enzyme by insulin is triosephosphate isomerase 1 (TPI1) 
(16.7 fold down) that catalyzes the reversible interconversion of the triosephosphate isomers 
dihydroxyacetone phosphate and D-glyceraldehyde 3-phosphate of the glycolytic pathway 
(Nagano N, et al. 2002). The depletion of TPI1 could counteract the effect of increased HK2 
expression/activity, providing further explanation for the limited glycolysis seen in 
insulin-treated cells.  
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Figure 3.6 List of glucose metabolic genes included in the glucose metabolism array 
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(A)  LPA 
 
3D Profile 1 2 3 4 5 6 7 8 9 10 11 12
A 2.58 1.36 1.31 1.15 1.26 0.94 0.68 0.72 1.45 1.51 1.11 1.36
B 1.99 1.05 0.93 0.63 0.27 1.95 1.38 1.18 1.05 0.26 1.7 0.94
C 1.13 1.37 1.9 3.25 0.72 1.22 39.32 0.79 0.57 1.12 2.42 1.23
D 1.58 0.84 0.11 1.78 1.45 1.27 0.94 1.33 1.63 0.92 3.18 0.18
E 0.95 0.05 3.19 1.66 1.3 0.5 1.62 0.35 1.08 1.56 1.49 1.07
F 1.87 0.5 1.63 1.49 1.13 1.92 0.94 1.97 0.66 2.49 0.66 1.41
G 2.62 0.96 1.57 0.93 0.93 1.35 0.78 0.86 1.17 0.54 1.68 0.58
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(B)  EGF 
 
3D Profile 1 2 3 4 5 6 7 8 9 10 11 12
A 1.22 0.71 0.85 0.68 1.21 0.76 0.9 0.59 0.93 0.86 0.71 0.85
B 1.51 1.43 0.51 0.47 0.22 1.27 0.2 1.03 1.25 0.33 1.51 0.91
C 0.94 1.38 1.87 2.25 0.7 0.9 22.3 0.77 0.51 0.66 1.51 0.78
D 0.93 0.56 0.08 1.28 0.95 1.47 1.05 0.75 1.27 0.82 3.52 0.24
E 0.8 0.1 1.34 1.01 0.94 0.3 1.15 0.38 1.01 1.4 0.96 0.95
F 1.12 0.42 0.47 1.41 1.25 1.21 0.91 1.4 0.49 0.6 0.24 1.02
G 1.4 0.78 1.16 0.68 0.38 0.91 0.58 0.58 0.86 0.55 0.99 0.6
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(C)  Insulin 
3D Profile 1 2 3 4 5 6 7 8 10 11 12
A 1.76 1.16 1.39 0.94 1.33 0.8 1.32 1 1.31 1.06 0.86
B 1.43 1.38 1.51 1.02 0.47 1.53 1.06 1.47 0.8 1.17 0.97
C 1.17 1.23 1.27 1.53 2.73 1.65 4.2 2.23 1.13 1.67 1.17
D 1.1 1.09 0.99 1.63 1.32 1.52 0.97 0.96 1.17 1.97 0.69
E 1.34 0.45 0.96 1.26 1.15 1.71 1.11 0.41 1.28 0.99 0.25
F 1.11 0.94 0.79 0.74 0.75 1.23 0.97 0.97 0.91 1.3 1.01
G 1.17 1.08 1.27 0.88 1.05 1.16 0.95 1 0.67 0.06 0.2
 
 
 
Figure 3.7 Regulation of glucose metabolism gene expression by LPA (A), EGF (B), and 
insulin (C) in Caov3 cells. Shown were fold changes in gene expression (upper panel) and 
heatmap of the data (lower panel) of the glucose metabolism array.  
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Figure 3.8 Super induction of HK2 by LPA and EGF in Caov3 cells. 
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3.4 HK2 as a key mediator of the glycolytic response  
 
To further confirm the importance of HK2 in LPA-driven glycolysis, we examined 
effects of HK2 inhibitors on LPA-induced glycolysis. The 2-Deoxy-D-glucose (2-DG) is a 
glucose analog which can be converted to phosphorylated 2-DG (2-DG-P) by Hexokinase, 
but it cannot undergo remaining steps of glycolysis because of its 2-hydroxyl group. 
Consequently, HK2 was trapped with this analog of glucose. As shown in Figure 3.9, LPA 
strongly stimulated the glycolysis rate. However, the rate was decreased significantly when 
2-DG (10 mM) was present (Figure 3.9 upper panel). Moreover, we utilized another HK2 
inhibitor, 3-Bromo-2-oxopropanoic acid (3-BrPA) to confirm the role of up-regulated HK2 in 
activation of glycolysis by LPA. This inhibitor is a pyruvate analog. It directly binds 
glyceraldehyde 3-phosphate-dehydrogenase. However, most studies show that 3-BrPA is a 
potent irreversible inhibitor of HK2 and effectively blocks glycolysis (Geschwind JF et al. 
2004; Ko YH et al. 2001). Figure 3.9 (bottom panel) showed that the glycolysis rate was 
significantly reduced by 3-BrPA (75 μM) in both Caov3 and OVCA432 cell lines. These 
results indicated that HK2 is the important glycolytic enzyme required for promoting 
glycolytic response to LPA. 
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Figure 3.9 Effects of the HK2 inhibitors on LPA-induced glycolysis in Caov3 and OVCR432 
cells.  
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3.5. Cellular impacts of hyperactive glycolysis  
 
If ovarian cancer cells display similar proliferation in association with different extents 
of glycolysis, one would expect different phenotypes of the cells grown under these growth 
factors. An advantage of hyperactive glycolysis is believed to provide precursors for 
biosynthesis of macromolecules essential for formation of daughter cells. Thus we examined 
the morphology and size of cells treated with LPA, EGF, insulin or IGF-1. The LPA and 
EGF-treated cells looked larger and more flat than insulin and IGF-1-treated cells under 
microscope (data not shown). To measure cell size, we typsinized the cells and scanned with 
Bio-Rad TC
10
 automatic cell counter. A population of more than 1x10
6
 cells was analyzed. As 
shown in Figure. 3.10, both peak value and cell size range were right shifted in LPA and EGF 
stimulated cells compared to insulin and IGF-1-treated cells. These results suggest that the 
cells grown with LPA or EGF had larger volumes than insulin and IGF-1-treated cells, 
consistent with the hypothesis that active glycolysis contributes to biosynthetic processes to 
maintain cell size.  
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Figure 3.10 Differences in volumes of Caov3 cells grown with LPA, EGF, insulin and IGF-1 
as determined by analysis of cells in suspension with the TC
10
 automated cell counter.  
Caov3 Peak Value (μM) Cell Size Range (μ M)
BSA 16 10-22
LPA 18 12-25
EGF 18 12-25
IGF 16 11-22
Insulin 16 10-23
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3.6 Potential role of EGFR in LPA-driven glycolysis 
 
There was significant overlap in up and down-regulation of glucose metabolic genes 
responsive to LPA and EGF (Figure 3.7), suggesting certain common mechanisms or 
signaling networks shared by LPA and EGF. It has been shown previously that LPA could 
“trans-activate” EGFR or other RTKs to exert its biological functions. To test this possibility, 
we used a commercial compound, Dacomitinib (PF00299804), which is an irreversible EGFR 
tyrosine kinase inhibitor. As shown in Figure 3.11, LPA-induced glycolysis and cell 
proliferation were both strongly inhibited by 1.25 μM PF00299804, suggesting that these 
actions of LPA may involve transactivation of EGFR. 
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Figure 3.11 Blockade of LPA-induced glycolysis (left, A) and cell proliferation (right, B) by 
EGFR inhibitor PF00299804 in Caov3 cells. (the numbers of cells prior to treatment were 
subtracted). 
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CHAPTER 4 
 
 
DISCUSSION 
 
An altered metabolic pattern was discovered by Dr. Otto Warburg nearly a century ago 
(Warburg O. 1956). Most tumor cells prefer producing energy by a high rate of aerobic 
glycolysis, an inefficient pathway for ATP production (2 ATPs/glucose), compared to a low 
rate of complete oxidation of pyruvate through the TCA cycle and mitochondrial respiration, 
a much more efficient way to generate bioenergy (36 ATPs/glucose). This seems to be a 
paradox for actively proliferative tumor cells. However, substantial evidence supports the 
importance for active glycolysis in rapidly growing tumor cells (Lnt SY. et al. 2011). The 
process provides not only a quick way to generate ATP from substrate-based phosphorylation, 
but also glycolytic intermediates for biosynthesis of amino acids, lipids and other 
macromolecules (Lnt, SY, et al. 2011; Cairns, RA, et al. 2011). Inhibition of glycolytic 
enzymes such as HK2, phosphofructokinase (PFK), GADPH, and lactate dehydrogenase 
(LDH) has been shown to prevent cell growth, survival, drug resistance and tumorigenesis in 
various types of cancer (Scatena, R, et al. 2008; Chen, Z, et al. 2007), thus offering a 
potential therapeutic opportunity. However, these inhibitors are non-selective blockers of 
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glucose metabolism in both normal and cancer cells (Chen, Z, et al. 2007), a major concern 
with their application to cancer patients. An innovative approach is to target hyperactive 
glycolysis specifically in tumor cells. This goal will depend on identification of etiological 
determinants that promote glycolysis in cancer cells. 
However, the etiological mechanism that governs the glycolytic switch from aerobic 
respiration in cancer cells remains poorly understood. Hypoxia and acidic pH could stimulate 
glycolysis through stabilization of the hypoxia-inducible transcription factor (HIF) to activate 
transcription of glycolytic enzymes. However, hypoxia and acidic microenvironments are not 
the causal factors underlying the glycolytic phenotype that occurs in both hypoxic and 
oxygenated regions of a tumor (Onnis B. et al. 2009; Wang GL. et al. 1995). Tumor cells in 
vitro also prefer glycolysis when cultured in normoxic and neutral conditions. When activated, 
the Ras, AKT, and c-Myc oncognes could upregulate expression of a variety of glycolytic 
genes (Riddle SR. et al. 2000; Allen CB. et al. 1998). In contrast, loss of the tumor suppressor 
p53 inhibits the mitochondrial respiratory chain via suppression of SCO2 (the synthesis of 
cytochrome c oxidase protein) and promotes glycolysis via TIGAR, a p53-inducible regulator 
of glycolysis and apoptosis (Kim JW. et al. 2006). Finally, the mitochondrial respiratory 
function can be negatively affected by mutations in mitochondrial DNA. However, these 
defects are present only in fractions of human tumors and do not explain the generally altered 
glucose metabolism in a wide spectrum of cancers. Other unrecognized mechanisms are 
likely important in the development and maintenance of the glycolytic phenotype of 
malignant cells. 
Our laboratory is interested in studying the molecular mechanisms behind metabolic 
abnormalities in cancer cells including the lipogenic and glycolytic phenotypes. It is expected 
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that identification of specific cancer-associated mechanisms could lead to new strategies to 
target cancer in a cancer cell-specific manner without toxic effects on normal cells. The lab 
has recently discovered that LPA, an ovarian cancer mediator found at high levels in tumor 
microenvironments, promotes de novo lipid synthesis via the sterol regulatory element 
binding protein (SREBP)-FAS and AMP-activated protein kinase (AMPK)-ACC pathways in 
ovarian cancer cells (Mukherjee, A, et al. 2012). Following this work, the lab has further 
extended to study whether LPA has a more profound influence on glucose metabolism. The 
objective of my thesis project was to explore the effect of LPA on glycolysis and the 
comparison of LPA with other important growth factors in their capability to regulate the 
glycolytic pathway in ovarian cancer cells. 
This work represents a new direction in the study of cancer-associated glycolysis. There 
has been no systemic analysis of the potential of growth factors in driving glycolysis in 
cancer cells. Previous studies have focused on roles of genetic alterations in the determination 
of the Warburg effect. Based on our results, the cells incubated in the absence of growth 
factors did not undergo excessive glycolysis (Figure 3.4 and Figure 3.5). These ovarian 
cancer cell lines, such as Caov3 and OVCA432, are p53 deficient and overexpress c-Myc and 
other oncogenes, suggesting that intracellular genetic mutations are insufficient to cause 
hyperactive glycolysis. When growth factors were supplemented, ovarian cancer cell lines 
increased glycolytic flux, mimicking the glycolytic phenotype seen in vivo. Thus extacellular 
environmental factors are involved in cooperation with intracellular genetic defects in the 
full-scale activation of glycolysis in cancer cells. So it is important in the future to study the 
role of tumor environments in the development and maintenance of hyperactive glycolysis in 
cancer cells. 
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By comparing the effects of LPA, EGF, insulin and IGF-1 on cellular glycolysis and 
lactate efflux, an interesting finding we made is that these growth factors are not equally 
glycolytic. LPA and EGF are significantly more potent than insulin and IGF-1 although they 
could stimulate comparable levels of cell proliferation. This suggests that the cell 
proliferation is not directly proportional to the glycolytic rate. The finding will open up an 
new avenue for us to analyze the quantitative contribution of glycolysis to cell proliferation. 
For example, if we reduce glycolytic levels partially in LPA and EGF-stimulated cells to that 
observed in insulin or IGF-1-treated cells, can we maintain the proliferative response to LPA 
or EGF? If not, there exist certainly two types of growth factors that rely upon different levels 
of glycolytic reactions to support cell proliferation. LPA and EGF represent the first type that 
is highly glycolytic while insulin and IGF-1 are the second type demonstrating weakly 
pro-glycolytic action. If this is also true in vivo, LPA and EGF are more likely to be 
endogenous factors contributing to the glycolytic phenotype of tumors. 
Substantial evidence supports the importance of LPA and EGFR in ovarian cancer. They 
are both potent growth, survival and metastatic factors in ovarian cancer. It has been known 
that abnormal LPA metabolism and receptor expression contribute to ovarian oncogenesis (Yu, 
S, et al. 2008; Tanyi, JL, et al. 2003; Li, H, et al. 2010) although the precise role of LPA in 
ovarian oncogenesis is not understood. On the other hand, EGFR and other members of 
EGFR family are overexpressed in ovarian cancer (Walker F. et al. 2009). Overexpression of 
these RTKs of EGFR family correlates with the aggressiveness and poor prognosis of ovarian 
cancer (Lynch TJ. et al. 2004). The current observation that LPA and EGF are strong 
glycolytic promoters provides a novel biological function of these factors to mediate the 
Warburg effect of aerobic glycolysis. 
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To examine the molecular mechanism underlying the differential effects of LPA, EGF, 
insulin and IGF-1 on glycolysis, we carried out glucose metabolism arrays to look for a gene 
signature potentially responsible for driving the high degree of glycolysis in LPA and 
EGF-stimulated cells. Among the glycolytic genes, the most remarkable change induced by 
LPA and EGF was the dramatic induction of HK2, the first key enzyme in the glycolytic 
pathway that stimulates the irreversible step of glucose phosphorylation. In Caov3 cells, 39 
fold up-regulation by LPA, a 22 fold up-regulation by EGF, and a much more modest 4.2 fold 
induction by insulin were observed. If HK2 is critical for driving glycolysis, the differential 
induction of HK2 by LPA, EGF and insulin may explain their differential abilities to activate 
glycolysis. 
To confirm that HK2 is indeed a critical player in LPA-induced glycolysis, we took 
advantage of two specific HK2 inhibitors: 2-DG and 3-BrPA. Both significantly reduced 
LPA-driven glycolysis. We also performed siRNA to knockdown expression of HK2 to seek 
molecular evidence that the HK2 induction is involved in activation of glycolysis by LPA. We 
observed partial inhibition of LPA-induced glycolysis (data not shown). The partial inhibition 
was understandable because it was difficult for siRNA to efficiently knockdown 39 fold 
induction of HK2 mRNA by LPA. 
It is worth noting that HK2 is overexpressed in majority of human malignancies (Wolf A. 
et al. 2008). Although no study has been conducted specifically to analyze HK2 expression in 
ovarian cancer, the microarray data publically available from the Oncomine database indicate 
that HK2 expression is generally increased in ovarian cancer compared to normal ovary 
tissues (data not shown). However, the mechanism for up-regulation of HK2 in ovarian 
cancer is unknown. LPA and EGF may be important factors responsible for HK2 
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overexpression in primary tumors. 
In addition to striking induction of HK2 by LPA and EGF, we also observed significant 
overlap in expression profile of other glucose metabolic genes such as down-regulation of 
PDK2 and PDK4 in LPA and EGF-treated cells. Although the significance of the regulation 
of these genes is beyond the scope of the current study, the overlap itself suggests common 
mechanisms or signaling networks shared by LPA and EGF. It has been shown previously 
that LPA could “trans-activate” EGFR or other RTKs in LPA mediated biological functions 
(Zhao Y. et al. 2006). This crosstalk between LPA EGFR may act through production of 
EGFR ligands or through EGFR ligand-independent mechanisms. When the EGFR small 
molecule inhibitor PF00299804 was added to culture, we found that LPA-induced glycolysis 
and cell proliferation were attenuated, suggesting that these actions of LPA involve activation 
of EGFR and probably EGFR downstream signals. However, the nature of the interactions 
between LPA GPCR and EGFR signal transduction in regulation of glucose metabolic gene 
expression and the subsequent glycolysis and cell proliferation remains to be investigated. 
Another interesting finding in this thesis work was the differences in morphology and 
size ranges of cells grown in LPA or EGF-treated conditions from those grown with insulin 
and IGF-1. We observed that LPA or EGF-stimulated cells showed more flat morphology and 
greater size compared to insulin or IGF-1-treated cells. The observation is consistent with the 
hypothesis that hyperactive glycolysis might serve to provide biosynthetic precursors. This is 
important for duplication of cellular contents, including DNA, proteins and membrane lipids, 
to maintain mass and dimensions of daughter cells. In this context, ATP generation by 
glycolysis may become secondary to the main aim, biosynthesis in rapidly growing tumor 
cells. 
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